BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.
What BALAXI files
- Others58
- Important17
- Board Meeting12
- PPTs8
- Credit Ratings3
- Insider Trade3
Balaxi Pharma delivered a strong Q1 FY27 performance, with consolidated revenue up 14% YoY to ₹80.68 Cr. Profit after tax (PAT) surged 347% to ₹1.29 Cr, while gross profit margin expanded by 241 basis points to 46.5%. Africa and LATAM contributed 54% and 46% respectively to revenue, with generics making...
Balaxi Pharma's FY26 revenue dipped 7.7% to ₹270.17 Cr, with Profit After Tax (PAT) dropping 94.3% to ₹1.42 Cr. This was primarily due to extended working capital cycles in its Angola institutional business. Positively, LATAM revenue grew 11%, and gross margins improved to 44.2%. The company is strategically transitioning to...
Balaxi Pharma reported Q3 FY26 revenue of 72.54 Cr, a marginal 1% dip year-on-year, but a strong 29% quarter-on-quarter jump. Revenue growth was primarily driven by the LATAM region, despite challenges in Angola impacting the institutional and hospital business. Gross profit margin moderated to over 42% (from 48% last year)...
Balaxi Pharma saw a challenging Q2 FY26 with revenue down 27% YoY to ₹56.17 Cr, impacted by softer demand, working capital pressure, and shipping delays. Profit after tax fell 95.4% to ₹0.21 Cr, partly due to increased operational costs from a strategic shift to institutional markets. However, gross profit margin...
Here's a summary of the attached file: **Financial Highlights:** Q1 FY26 revenue grew 8% YoY to ₹70.74 Cr, maintaining a 44% gross margin. Profit After Tax sharply declined to ₹3.29 Cr (vs ₹6.48 Cr in Q1 FY25), attributed to higher operational costs including one-time write-offs and the Nicaragua business not...